Furthermore, 26 was ineffective at affecting the viability of a GBM cell line expressing mutant p53, whereas it was able to reduce the proliferation of glioma cancer stem cells, cells within the tumor that are resistant to therapies and responsible for GBM recurrence. The gene discussed is TP53; the disease is glioblastoma.